Scienza e Tecnologia
Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion
"Enzymatica's progress and future prospects are clearly reflected in the strong first quarter of 2025. ColdZyme continues to perform strongly in the pharmacy sector, growing faster than the overall market and resulting in additional market share gains. Sales increased by 31.5% in Sweden and 19.5% in the UK compared to the same period last year – clear proof that ColdZyme is both reaching consumers and being appreciated.
However, sales in our home markets represent only a small part of our future vision, and our patented technology paves the way for significant sales growth – through new markets and partnerships," says Claus Egstrand, CEO.
On March 5, 2025 , Enzymatica held a press conference, both physically and digitally, where Professor Glen Davison and Professor Doris Wilflingseder presented their findings from the recently published article . The presentation was followed by a company update. Both recordings are available for viewing on the company's website.at https://www.enzymatica.com/media/articles-insights/replay-of-the-press-conference-on-coldzyme-march-5-2025/
Claus Egstrand, CEO, Enzymatica AB
Mobile: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Enzymatica AB is headquartered in Lund and is listed on the Nasdaq First North Growth Market. For more information, visit www.enzymatica.se.
Enzymatica's Certified Adviser is Carnegie Investment Bank AB (publ).
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/enzymatica-ab/r/quarterly-report-q1-2025--enzymatica-strengthens-its-position-in-home-markets-and-focuses-on-interna,c4142245
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/quarterly-report-q12025-enzymatica-strengthens-its-position-in-home-markets-and-focuses-on-international-expansion-302440852.html